MultiBank Group Reveals Record-Breaking Financial Figures for 2020 with an Annual Turnover of over US$ 5 Trillion
25.5.2021 13:31:00 EEST | Business Wire | Press release
MultiBank Group, World’s number 1 Forex and CFD broker, reveals record financial figures for 2020. The award-winning financial services company announced gross profit of over US$ 139 million for the year, making an impressive 62% increase from 2019’s result of over US$ 85 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005496/en/
MultiBank Group Reveals Record-Breaking Financial Figures for 2020 with an Annual Turnover of over US$ 5 Trillion (Graphic: Business Wire)
Remarkably, MultiBank Group’s annual turnover for 2020 was recorded at over US$ 5 trillion, marking a record-breaking year for the global giant. With figures such as these and consistently robust growth, it is no wonder that MultiBank Group is one of the largest financial derivatives providers worldwide.
The MultiBank Group through its subsidiaries are the most heavily regulated Group through 5 continents with 11 regulators worldwide, setting a high standard for the industry and ensuring unprecedented transparency for its clients. The Group has continued to see growth across its key metrics year on year which has been underpinned by exceptional performance across its key areas of strategic focus and the dexterity of technology infrastructure.
The MultiBank Group maintains 25 branches worldwide, in Australia, Germany, Austria, Spain, Cyprus, USA, Mexico, UAE, Kuwait, Jordan, Turkey, South Africa, Nigeria, China, Hong Kong, Singapore, Malaysia, Philippines, Vietnam, British Virgin Islands, Cayman Islands and Vanuatu.
Naser Taher, Chairman of MultiBank Group, says:
“2020 was a monumental year to say the least, and I am so proud of these record-breaking financial figures. The results are a testament to our commitment to providing our clients with award winning technologies, platforms, and services, and of course to our fantastic team. The results from 2020 give us continued motivation to keep pushing forward to maintain our strong position in the market. We have high hopes for 2021 and are excited to continue growing as a company.”
For more information about the MultiBank Group, please visit www.multibankfx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005496/en/
Contact information
Media Enquiries:
Rena Chehayber | Marketing & Brand Communication Manager | MultiBank Group
Email: rena.chehayber@multibankfx.com
Phone: +971 487 513 50
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vasion Output ™ from Vasion Achieves SAP ® Certified Integration with GROW for SAP and with RISE with S/4HANA ® Cloud24.2.2026 15:00:00 EET | Press release
Vasion, a leader in serverless printing and Intelligent Print Automation, today announced that Vasion Output has achieved SAP® certification as integrated with GROW with SAP and integrated with RISE with SAP S/4HANA® Cloud. The Vasion solution is purpose-built to eliminate legacy output management as a cloud migration barrier. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224741412/en/ Chee Tan, Vice President of Ecosystem & Alliances at Vasion, leads Vasion’s global strategic ecosystem partnerships. He drives the integration of AI-powered output management and document workflows with leading enterprise solutions such as SAP S/4HANA, enabling organizations to modernize print infrastructure, consolidate environments, and automate enterprise document workflows. The certification confirms what enterprise resource planning (ERP) customers moving to S/4HANA need most: proven infrastructure that handles mission-critical docume
NorthX Biologics and Demeetra Announce Strategic Collaboration to Deliver a Faster, Lower-Risk Path from Gene to GMP24.2.2026 15:00:00 EET | Press release
NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom to operate and no additional IP-related costs, together with advanced cell line development technologies and high-quality process development, MCB banking, and GMP manufacturing services. The collaboration is designed to help biotech companies reach IND-enabling and clinical milestones faster, with fewer technical setbacks and without the need to rebuild cell lines or re-qualify processes when transitioning to a manufacturing partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224427714/en/ Supporting stable, high-titer cell line development and seamless GMP advancement. The partnership combines Demeetra’s CleanCut™ CHO platforms and stable CLD services with NorthX Biologics’ proven GMP production capabilities, process scale-up expertise including fill and finish, and re
ExaGrid Wins New Industry Award24.2.2026 15:00:00 EET | Press release
ExaGrid®, the leader in Tiered Backup Storage, today announced that it has been honored with an award in the Secondary Storage category from the first annual StorageNewsletter Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224387048/en/ ExaGrid Tiered Backup Storage wins the award for Secondary Storage for the first annual StorageNewsletter Awards. The winners of the StorageNewsletter Awards were chosen by a seven-member jury who selected the vendors for each category. “A long-standing innovator, ExaGrid has played a key role in shaping a new era of secondary storage with its scale-out architecture. Originally built around HDDs, the platform now supports SSDs and continues to gain market share at a rapid pace, driven by a strong channel ecosystem and broad validation from numerous backup software vendors. Through continuous feature enhancements, the team has led this segment for many years, and the outlook for fut
Axelera AI Secures More Than $250 Million Funding on Global Commercial Growth24.2.2026 15:00:00 EET | Press release
Axelera AI, the European leader in AI acceleration hardware, announced its latest funding round led by Innovation Industries, with participation from prominent funds and accounts including BlackRock and SiteGround Capital as new investors, as well as existing investors Bitfury, CDP Venture Capital, European Innovation Council Fund, Federal Holding and Investment Company of Belgium (SFPIM), Invest-NL, Samsung Catalyst Fund, and Verve Investments. Axelera AI has attracted over $450 million in equity, grants and venture debt since incorporating in July 2021. The largest investment ever in an EU AI semiconductor company comes as Axelera ships to its 500th global customer across physical AI and edge AI in industries including defense and public safety, industrial manufacturing, retail, agritech, robotics, and security, firmly establishing the company as the global leader in power-efficient AI inference solutions. Axelera AI’s success is rooted in a fundamental insight: to deploy AI at scale
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 202624.2.2026 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ADVC001 in metastatic prostate cancer. ADVC001 is an investigational Lead-212-based prostate-specific membrane antigen (PSMA)-targeted alpha therapy. The study design will be showcased in a ‘Trials in Progress’ poster this week at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) in San Francisco, CA. The TheraPb Phase 2 is an open-label, randomized expansion study incorporating dose optimization strategies in three groups of patients with metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). The study’s innovative design is supported by the Phase 1b dose escalation results, which showed encouraging safety and promising anti-tumor activity of ADVC001. At the recommended Phase 2 dose, 80% of patients achieved a 50% reducti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom